BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Company News  |  Other News

Myrexis cancer news

Myrexis will restructure and reduced headcount by 57 (41%) to 81 and will focus resources on its pipeline of cancer candidates. The reductions primarily came from Myrexis' internal drug discovery group and include VP General Counsel Andrew Gibbs. Additionally, the biotech said it will close its research services business....

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >